Investigation of Clofazimine Resistance and Genetic Mutations in Drug-Resistant Mycobacterium tuberculosis Isolates

Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis

(2020) Yuhong Liu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Clofazimine for Treatment of Extensively Drug-Resistant Pulmonary Tuberculosis in China

(2018) Qingfeng Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms

(2018) Sudhir Kumar et al.   MOLECULAR BIOLOGY AND EVOLUTION

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

(2018) Nafees Ahmad et al.   LANCET

Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters

(2017) Joseph S. Cavanaugh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Delamanid and Bedaquiline Resistance inMycobacterium tuberculosisAncestral Beijing Genotype Causing Extensively Drug-Resistant Tuberculosis in a Tibetan Refugee

(2016) Harald Hoffmann et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mutations inpepQConfer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

(2016) Deepak Almeida et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline

(2015) Andreas H. Diacon et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis

(2015) Benoit Lechartier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro synergistic activity of clofazimine and other antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis isolates

(2015) Zhijian Zhang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Identification of novel mutations associated with clofazimine resistance inMycobacterium tuberculosis: Table 1.

(2015) Shuo Zhang et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis

(2015) Guido V. Bloemberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment: TABLE 1

(2014) Akos Somoskovi et al.   EUROPEAN RESPIRATORY JOURNAL

Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients

(2014) K. J. M. Aung et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline

(2014) Koen Andries et al.   PLoS One

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [Review article]

(2013) M. Gopal et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters

(2012) J. Xu et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis

(2011) T. Schön et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

(2010) Armand Van Deun et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone Oxidoreductase

(2010) Takahiro Yano et al.   JOURNAL OF BIOLOGICAL CHEMISTRY